Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

14 treatments under study, led by Nivolumab

Research Leaders

14 sponsors active, led by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

22.2%

2 terminated out of 9 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results50% success

Data Visualizations

Phase Distribution

7Total
Not Applicable (2)
Phase 1 (1)
Phase 1/2 (1)
Phase 2 (3)

Trial Status

Recruiting2
Terminated2
Completed2
Not Yet Recruiting1
Active Not Recruiting1
Unknown1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05917860Phase 1Active Not Recruiting

Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer

NCT07393867Phase 2RecruitingPrimary

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

NCT06117059Not ApplicableRecruiting

The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance

NCT03815942Phase 1/2TerminatedPrimary

VAccination in Early and ADvanced Prostate caNCEr

NCT03740191Not ApplicableTerminated

Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer

NCT02028988Phase 2CompletedPrimary

Enzalutamide + External Beam Rt For Prostate

NCT03340272UnknownPrimary

PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.

NCT01379872Completed

Assessment of New Radiation Oncology Technologies and Treatments

SYF3a1144db706e49f3a796d85dbd234ebfPhase 2Not Yet Recruiting

Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO trial)

Showing all 9 trials

Research Network

Common Treatments

  • Nivolumab1
  • Noninterventional Study1
  • Stereotactic Body Radiation Therapy Sbrt Focal Microboost1
  • Psma Petct1
  • 3 Fractions Of Prostate Sbrt1

Active Sponsors

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia1
  • Fondazione Radioterapia Oncologica Onlus1
  • Martin T. King, MD, PhD1
  • NHS Lothian1
  • EBG MedAustron GmbH1

Top Investigators

Related Conditions

  • Prostate Cancer2
  • Low Risk Prostate Cancer2
  • High Risk Prostate Cancer2
  • Localized Prostate Cancer1
  • Castrationresistant Prostate Cancer1

Activity Timeline